This page shows the latest Heron Therapeutics news and features for those working in and with pharma, biotech and healthcare.
Concentric specialises in novel non-opioid pain therapeutics, and CA-008 is a first-in-class non-opioid therapeutic that rapidly converts to capsaicin, a potent TRPV1-agonist. ... The announcement follows a BTD in June for Heron Therapeutics and its
for postoperative pain management, in phase III studies,” said Barry Quart, Heron’s chief executive. ... March that Exparel sales would fall off dramatically if HTX-011 is approved – particularly as she thinks Heron’s drug is likely to be cheaper.
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...